Biotech M&A – 2020 Deals

Biotech M&A – 2020 Deals

Biotech M&A With a Slow Start in 2020: More Deals to Follow?

DateAcquirer Co.Acquirer TickerAcquired Co.Acquired TickerDeal valuePrice/ShareCVR (if any)Notes
01/10/2020Eli LillyLLYDermiraDRMA$1.1B$18.75chronic skin conditions
03/03/200GileadGILDForty SevenFTSV$4.9B$95.50CD47 for AML & MDS
05/04/2020Menarini Group-ItalyPrivateStemline TherapeuticsSTML$677M $11.50CVR $1CD123 ELZONRIS Oncology
05/05/2020Alexion PharmaceuticalALXNPortola PharmaceuticalPTLA$1.41B$18CVR $6.00 upon FDA acceptance of the NDA filing (+$263M)Uncontrolled bleeding
Factor Xa inhibitor
08/17/2020SanofiSNYPrincipia BiopharmaPRNB$3.68B$100BTKi for MS
08/19/2020Johnson & JohnsonJNJMomentaMNTA$6.5B$52.20FcRn inhibitor, treatment of autoantibody-driven autoimmune diseases
08/31/2020Nestlé, S.A.part of Nestlé Health Science (NHSc)Aimmune TherapeuticsAIMT$2.6B$34.50PALFORZIA,treatment for food allergy (peanuts)
08/31/2020Ionis PharmaceuticalsIONSAkcea TherapeuticsAKCA$500M$18.15to acquire remaining 24% of common stock
09/13/2020GileadGILDImmunomedics IMMU$21$88Trodelvy-Breast cancer

For M&A 2019 full table click here https://www.chimeraresearchgroup.com/biotech-ma-2019-deals/

Recent Press

Slider

Log In

JoinLost Password?